259 results about "Ischemia" patented technology

The invention is a delivery catheter, e.g., a guide catheter, having an imaging element in proximity to the distal end of the catheter. Catheters of the invention are able to placement of the catheter in proximity to an ostium, thereby increasing the efficiency of contrast delivery while reducing the risk of ischemia due to blocked blood supply. The invention additionally assists in maintaining catheter position during delivery of a fluid from the catheter, resulting in better performance with less fluid. For example, a catheter of the invention can be used to produce improved fluoroscopic images with less overall contrast. This improvement reduces the risk of an allergic reaction to the contrast while decreasing the length of time for a procedure, i.e., because of a need to re-contrast.

The invention provides an intravascular occluder which comprises an occluder body, a catheter part and a control mechanism, the occluder body is of an umbrella-shaped structure formed by a plurality of frameworks which can be opened, and a layer of covering is attached to the occluder body; the catheter part is used for accommodating the plugging device and the connecting rod part of the control mechanism; the control mechanism comprises a connecting rod part and a handle control part, and is used for controlling the pushing and withdrawing of the plugging device; after the plugging device is unfolded to completely plug the inner diameter of the blood vessel, the function of cutting off blood flowing can be achieved, a space for blood flowing can be reserved at the position close to the inner wall of the blood vessel by properly retracting the plugging device into the catheter, and the plugging device can be completely retracted into the catheter by completely retracting the plugging device. The device has the advantages that unfolding and folding are completely reversible, controllable opening and cutting of blood flow can be achieved, complications caused by long-time ischemia of blocked blood vessels can be avoided, and a long-time operation becomes possible.

The invention discloses a man-machine suitability evaluation method for a mattress, and relates to the field of human engineering health monitoring, and the method comprises the steps: screening testers according to a BMI grading standard, and collecting the height, weight, gender, age, sleep habit and chronic pain medical history basic data of the testers to obtain the BMI values of the testers; inputting the BMI value of the tester into the mattress hardness selection model to obtain the hardness range of the tested mattress, arranging a to-be-tested mattress with selected hardness in a constant-temperature and constant-humidity experimental environment, and enabling the tester to lie on the to-be-tested mattress in sequence at a standard supine position and a standard lateral position. According to the method, the spine stiffness demand curve is predicted in real time through the LSTM neural network, millisecond-level dynamic support adjustment is achieved, the response speed is remarkably increased compared with a traditional method, and spine compensatory bending in sleep can be prevented; and in combination with pressure-blood oxygen coupled IRI index calculation, microcirculation disturbance is accurately warned before tissue injury, and the problem of local ischemia is solved through partition adjustment.

The invention discloses a local oxygen therapy, flushing and skin stretching device for chronic wound treatment, and relates to the technical field of medical apparatuses and instruments, the local oxygen therapy, flushing and skin stretching device comprises a stretching disc, and a cleaning device is arranged in the middle of the stretching disc; according to the device, breakthrough is achieved through the combination of the circular structure of the stretching disc and the circumferentially-distributed T-shaped sliding racks; the circular geometric structure of the stretching disc has stress symmetry, and stretching force can be evenly dispersed; the position of the T-shaped sliding rack installed in a circumferential sliding mode can be flexibly adjusted in the radial direction of the stretching disc, and six or more stretching points can be set at will according to the boundary of the wound surface in cooperation with the sliding block and the T-shaped hook frame which can slide. For example, for an irregular polygonal wound surface of a diabetic foot, a medical worker can mark six stress balance points on the T-shaped sliding rack and fix the hook, synchronous or independent adjustment of multiple distraction points is achieved through linkage of the rotating gear ring and the multiple sets of gears, and the situation that skin ischemia blister is caused by too large local stress or tissue stretching is affected by insufficient stress is avoided.

The invention relates to the technical field of intraoperative intelligent monitoring, and particularly discloses a spinal canal debonding method and system for real-time state evaluation, and the method comprises the steps: collecting neural structure microcirculation blood flow data in real time through integrating a micro-sensing unit at a working end part of a surgical instrument, and extracting blood flow oscillation frequency and capillary hematocrit parameters; performing multi-scale signal decomposition on the blood flow oscillation frequency to obtain an energy distribution parameter, and performing dynamic mode recognition on the hematocrit data to obtain a main variation characteristic value; fusing the two characteristic parameters to generate a nervous tissue vitality index; inputting the index into a pre-trained neural network for time sequence feature analysis, and outputting a graded ischemia risk early warning signal; the operation rhythm is automatically adjusted through a decision tree control mechanism based on the early warning signal, and self-adaptive regulation and control according to the state of the nervous tissue are achieved; the technical problem that the risk of neural ischemia cannot be monitored in real time in a traditional spinal canal release operation is solved, and occult nerve injury caused by asymptomatic neural ischemia can be prevented.

The invention provides a lipoic acid-based nano-enzyme and a preparation method and application thereof, firstly, lipoic acid is dissolved in an organic solvent by utilizing the amphipathy of the lipoic acid and is self-assembled in water to form a nano-aggregate, and then ring opening polymerization of the lipoic acid is initiated by ultraviolet irradiation to obtain stable lipoic acid nano-particles, namely the lipoic acid-based nano-enzyme. The lipoic acid-based nano-enzyme has the beneficial effects that the preparation method of the lipoic acid-based nano-enzyme prepared by the method is simple, the lipoic acid-based nano-enzyme has stable particle size, good active oxygen scavenging ability and blood brain barrier crossing ability, and in addition, a cavity in the nano-enzyme is suitable for loading hydrophobic bioactive factors and drugs, so that the lipoic acid-based nano-enzyme has a good application prospect. Rich carboxyl groups on the surface of the nano-enzyme can be complexed with various ions, and the nano-enzyme can be applied to treatment of inflammation diseases caused by hypoxia or ischemia and the like and brain drug delivery.

The invention relates to the technical field of stem cells, and particularly discloses application of mesenchymal stem cells (MSC) in treatment of lower limb vein ischemia. According to the application, the SDF1-FGF2 fusion protein is used for pretreating human mesenchymal stem cells (hMSCs), and the cell activity, the blood flow recovery capacity and the anti-inflammatory effect of the hMSCs in a lower limb vein ischemia model can be remarkably improved through pretreatment. The hMSCs pretreated by SDF1-FGF2 are injected into the body of a venous ischemia model mouse, and compared with untreated cells, the hMSCs have better effects in the aspects of improving blood perfusion, reducing inflammatory response, recovering motor function and the like. The method provides an efficient stem cell treatment strategy for vascular diseases such as lower limb vein ischemia.

The invention discloses an application and method of SAH-CIM hydrogel in promoting survival of retinal ganglion cells in glaucoma. The hydrogel comprises a Y-type primitive composed of three DNA chains and a siRNA connector, and the nucleotide sequences of the three DNA chains are SEQ ID NO.1-SEQ ID NO.3; the method comprises the following steps: S1, constructing a Y-type primitive: mixing three DNA chains with equal molar concentration in an annealing buffer solution, performing high-temperature denaturation at 95 DEG C, and then quickly cooling to 4 DEG C to finish annealing, so as to form a stable Y-type structure with three-way cohesive ends; s2, synthesizing a siRNA (small interfering Ribonucleic Acid) connector; and S3, mixing the Y-type element and the siRNA connector according to a molar ratio of 1: 1.5 at room temperature to react for 30 minutes, and forming a three-dimensional network structure through complementary pairing driven self-assembly, thereby finally obtaining the SAH-CIM hydrogel. The SAH-CIM hydrogel provided by the invention can be used for preventing / treating ischemia-reperfusion injury and related diseases, for example, the SAH-CIM hydrogel can be used for treating glaucoma, accurate co-delivery of a neuroprotective agent and an immunomodulator can be realized, and the SAH-CIM hydrogel has the advantages of treatment accuracy and biocompatibility.

The invention discloses an electrocardio data processing and coronary heart disease risk prediction method, device and system and a medium. The method comprises the steps of obtaining exercise electrocardio data output through at least one electrocardiogram lead; analyzing the exercise electrocardiogram data to obtain a heart rate sequence corresponding to each electrocardiogram lead; extracting a QRS wave group corresponding to each heart beat from the exercise electrocardio data; dividing a plurality of heart rate intervals according to the obtained heart rate sequence; according to the heart rate interval to which the heart rate corresponding to each QRS wave group belongs, classifying the QRS wave group into a group corresponding to the corresponding heart rate interval; determining an average QRS wave group corresponding to each heart rate interval according to all the QRS wave groups in each group; extracting the high-frequency energy of the average QRS wave group corresponding to each heart rate interval; and determining an energy sequence according to the high-frequency energy corresponding to each heart rate interval. According to the scheme, high-frequency components and dynamic load information which are more sensitive to ischemia are utilized, so that the detection rate and the identification capability of coronary heart diseases, particularly early and mild lesions, can be remarkably improved.

The invention discloses a perfusion balloon and a balloon dilatation catheter, and relates to the technical field of medical instruments. The perfusion balloon comprises a fillable body and at least one hollow component, a concave part and a convex part which are connected with each other at least in a full state are formed on the peripheral wall of the fillable body; the at least one hollow assembly is arranged on the peripheral wall of the fillable body and extends in the length direction of the fillable body, and the hollow assembly and the sunken part jointly form a blood flow channel allowing blood to pass through. The structure of the perfusion balloon is improved, a blood flow channel is formed between the periphery of the perfusion balloon and the blood vessel wall, fluid in the blood vessel is allowed to flow when the balloon expands, longer balloon expansion time is allowed, and the risks of ischemia and tissue damage are reduced.

The invention discloses a bionic bacterial outer membrane nano-particle for drug delivery. The bionic bacterial outer membrane nano-particle is characterized by comprising low-toxicity outer membrane vesicles extracted from escherichia coli with msbB genes knocked out, and low-toxicity outer membrane vesicles extracted from escherichia coli with msbB genes knocked out; the medicine carrying liposome is prepared from phosphatidylcholine, cholesterol and DSPE-PEG2000 (Distearoyl Phosphatidylcholine-Polyethylene Glycol 2000) according to a preset mass ratio; the low-toxicity outer membrane vesicles and the drug-loaded liposome are subjected to ultrasonic assistance and 100nm filter membrane extrusion to obtain bionic bacterial outer membrane nanoparticles, the average particle size of the bionic bacterial outer membrane nanoparticles is about 100nm, and the encapsulation efficiency exceeds 85%. The BM-NPs system disclosed by the invention can load small molecule compounds, proteins, nucleic acids and gene therapy vectors, and is suitable for various central nervous system diseases such as spinal cord injury, cerebral apoplexy, traumatic brain injury, ischemia-reperfusion injury and the like.

A system for monitoring medical conditions including pressure ulcers, pressure-induced ischemia and related medical conditions comprises at least one sensor adapted to detect one or more patient characteristic including at least position, orientation, temperature, acceleration, moisture, resistance, stress, heart rate, respiration rate, and blood oxygenation, a host for processing the data received from the sensors together with historical patient data to develop an assessment of patient condition and suggested course of treatment, including either suspending or adjusting turn schedule based on various types of patient movement. The sensor can include bi-axial or tri-axial accelerometers, as well as resistive, inductive, capacitive, magnetic and other sensing devices, depending on whether the sensor is located on the patient or the support surface, and for what purpose.

The flow-adjustable perfusion balloon catheter comprises a catheter body, a balloon capable of being filled and a catheter base, a push rod channel and a filling channel are arranged in the catheter body, the filling channel is communicated with an inner cavity of the balloon, and a first connector and a second connector are arranged on the catheter base. Micropores are formed in the positions, located at the near end and the far end of the balloon, of the catheter body and are the near-end micropore and the far-end micropore respectively, the near-end micropore and the far-end micropore are communicated through a blood flow channel formed in the catheter body, and a blocking piece capable of blocking the near-end micropore or the far-end micropore is arranged in the blood flow channel. A push rod is arranged in the push rod channel, and the far end of the push rod is connected with the near end of the plugging piece. Compared with the prior art, by arranging the blood flow channel, effective circulation of blood flow can still be achieved after balloon plugging in the operation, complications caused by ischemia or hypertension in the operation are avoided, the perfusion blood flow can be adjusted in time according to different patient conditions, and the success rate of the operation is increased.

The invention discloses a pancreas strapping tape capable of quantifying strapping pressure, and belongs to the technical field of medical instruments, the pancreas strapping tape comprises a first non-extension section and a second non-extension section, an elastic section and a limiting rope are arranged between the first non-extension section and the second non-extension section, and an insertion hole is formed in the head end of the first non-extension section. The quantitative binding force is provided for the pancreatic stump, sufficient bursting pressure can be provided for the main pancreatic duct, complete pancreatic ischemia and acute pancreatic necrosis caused by too high binding pressure are avoided, and the risk of pancreatic fistula and pancreatitis caused by acute pancreatic necrosis is reduced; due to the design of the limiting rope, whether preset binding tension is reached or not can be easily judged in the binding process; when pancreatic tissue is shrunk in the postoperative process, the strapping tape can still continue to provide strapping pressure through contraction of the elastic section, the strapping pressure generated in the postoperative process is reduced in a limited mode, enough bursting pressure can still be provided for the main pancreatic duct, and the risk of pancreatic fistula caused by insufficient bursting pressure of the main pancreatic duct is reduced.

The present invention relates to an injectable pre-formulation comprising:a) at least one of a mono-, di- or tri-acyl lipid and / or a tocopherol;b) optionally at least one phospholipid;c) at least one biocompatible, organic solvent; andd) at least one prostacyclin analogue or a salt thereof;wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with excess aqueous fluid. Such compositions may additionally comprise polar co-solvents. Methods of treatment, particularly for management of pulmonary artery hypertension (PAH), severe PAH, Raynaud's disease, ischemia and related conditions are provided, as well as corresponding uses of the compositions. Administration devices comprising the formulations and kits comprising the devices are also provided.

The utility model relates to medical instrument technical field especially is a kind of wearable femoral vein compression hemostasis device, including disposable underpants body, the upper surface of one side of trouser leg is located at femoral vein and is fixedly installed with the compression assembly for fixing wound, and the compression assembly includes clamping ring plate, the middle part of clamping ring plate is equipped with four groups of insertion slot, the surface both sides of waistband are fixedly installed with trouser loop, and the periphery of waistband is provided with the bandage assembly for exerting pressure and is set, and the bandage assembly includes waist bandage and leg bandage, the both ends of waist bandage are insertedly installed in the inside of insertion slot, the both ends of leg bandage are also insertedly installed in the inside of insertion slot, the both ends of waist bandage can be folded and detachably connected, and the both ends of leg bandage can be folded and detachably connected.The utility model is folded and detachably connected by underpants design, bandage, clamping ring plate disperses pressure, reduces the risk of local ischemia, and waist bandage and leg bandage synergistic effect, form three-dimensional compression.

A method, device, system and medium for electrocardio data processing and coronary heart disease risk prediction, motion electrocardio data output through at least one electrocardio lead is acquired; the motion electrocardio data is analyzed to obtain a heart rate sequence corresponding to each electrocardio lead; each QRS complex corresponding to each heartbeat is extracted from the motion electrocardio data; a plurality of heart rate intervals are divided according to the obtained heart rate sequence; each QRS complex is classified into a group corresponding to a heart rate interval according to the heart rate interval to which the heart rate corresponding to the QRS complex belongs; the average QRS complex corresponding to each heart rate interval is determined according to all QRS complexes in each group; the high-frequency energy of the average QRS complex corresponding to each heart rate interval is extracted; and an energy sequence is determined according to the high-frequency energy corresponding to each heart rate interval. The present scheme uses high-frequency components and dynamic load information which are more sensitive to ischemia, and can significantly improve the detection rate and discrimination ability for coronary heart disease, especially early and mild lesions.

The invention discloses a GLP-1 (32-36) engineered exosome and application of the GLP-1 (32-36) engineered exosome in drugs and instruments for preventing and / or treating diabetic lower limb arterial lesion. The preparation process and related characteristics of the GLP-1 (32-36) engineered exosome are respectively as shown in figures (1) and (2). The exosome is prepared by treating human pluripotent stem cells by using GLP-1 (32-36). The GLP-1 (32-36) engineered exosome has relatively high activity in plasma, and the enterotrypsin synthetic peptide can effectively improve the yield of the exosome and further optimize the function of the exosome, so that a stronger therapeutic effect of promoting angiogenesis after ischemia is exerted. The GLP-1 (32-36) engineered exosome disclosed by the invention also has safety and can be used for a treatment strategy of diabetic lower limb artery complications.

The present invention relates to compounds with high chemical stability and methods for inhibiting the pathological activity of extracellular histones in a subject. In particular, the invention relates to compounds with high chemical stability, uses thereof and methods for inhibiting or ameliorating extracellular histone mediated ailments (such as, for example, sepsis, systemic immune response syndrome (SIRS) and ischemia reperfusion injury (IRI)). More particularly, the invention relates to methods and uses of a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus, wherein the presence of the substituent results in a molecule with high chemical stability without affecting the ability of the molecule to be effective in the therapy of extracellular histone mediated ailments. For example, the present invention relates to methods and uses of β-O-methyl cellobioside sulfate (mCBS) or a pharmaceutically acceptable salt thereof (e.g., mCBS.Na), in the therapy of a range of extracellular histone mediated ailments in subjects.

The invention discloses a pressure monitoring device and method for evaluating pressure sore risk, and relates to the technical field of medical equipment. The system comprises a pressure sensing unit used for collecting pressure distribution data between the body surface of a patient and a supporting surface; the distance measuring device is used for measuring the distance between the device and the body surface of the patient. According to the method, information of three different dimensions of pressure distribution, body surface image and deep thermal imaging is subjected to fusion analysis, a pressure sensor positions a high-risk pressed area, a high-definition color image is used for identifying macroscopic skin damage and color change, infrared thermal imaging can penetrate through a surface layer, and the image can be used for identifying the skin damage and color change. According to the method, deep tissue temperature abnormity caused by ischemia and inflammation is sensitively captured, and the three types of information are integrated into a quantitative comprehensive risk score through a weighting algorithm, so that an evaluation result does not depend on subjective experience of nursing personnel any more and is converted into objective and quantifiable accurate diagnosis, and the screening accuracy of high-risk patients is remarkably improved.

The present disclosure relates to a method for reducing or hindering development of renal ischemia-reperfusion injury in a subject the method comprising administering an antibody that inhibits granulocyte colony stimulating factor (G-CSF) signaling. In some examples, the ischemia-reperfusion injury is due to or associated with tissue or organ transplantation.

The utility model relates to a catheter with a variable pipe diameter, and belongs to the technical field of medical instruments. Comprising a catheter body internally provided with a urinary catheterization channel. The first sleeve is coaxially connected to the outer part of the catheter main body in a sleeving manner; the elastic anchoring sleeve is coaxially connected to the exterior of the first sleeve in a sleeving mode, and a second annular channel is defined by the elastic anchoring sleeve and the outer wall of the first sleeve; and the pressure release structure is communicated with the second annular channel and is configured to be in an open state or a closed state based on the fluid pressure in the second annular channel. The elastic anchoring sleeve can reliably prevent excessive radial pressure applied to urethral mucosa due to excessive expansion of the elastic anchoring sleeve, so that serious complications such as ischemia, edema, pressure necrosis and even long-term urethrostenosis caused by long-term compression of local tissues are effectively avoided.

The invention belongs to the technical field of medicines, and particularly relates to application of penicillin tenuipes in preparation of a product for preventing or treating ischemic encephalopathy, cell experiments and animal experiments show that penicillin tenuipes has a good treatment effect on cerebral thrombosis and middle artery embolism, can obviously improve behavioral scores after ischemia, and can be used for preparing a medicine for preventing or treating ischemic encephalopathy. And cerebral thrombus and blood vessel diameter conditions. The penicillin tenuipes also has an anti-inflammatory effect. Therefore, the compound can be used for preparing medicines for preventing or treating ischemic encephalopathy.

The invention relates to the technical field of hemostasis, and discloses a medical wrist strap with a hemostasis function, which comprises a main body assembly, a wrist strap body and a locking assembly, an information nameplate is fixed on one side of the wrist strap body, the wrist strap body is made of an elastic bandage, the locking assembly is arranged on the wrist strap body and comprises a rotating part, and the rotating part comprises a fixed frame. The wrist strap has the beneficial effects that the wrist strap is made of an elastic bandage material and is matched with the locking assembly, when hemostasis is needed in emergency, hemostasis can be carried out on the bleeding part of a patient through the wrist strap, the length of the wrist strap can be adjusted, the wrist strap can be bound to different bleeding parts of the patient, and after hemostasis is carried out for a certain period of time, the wrist strap can be fixed. In addition, the wrist strap can be automatically relaxed for a short time and tightened again, so that blood circulation of the far end of the limb can be temporarily recovered, and serious injury, such as muscle necrosis, nerve injury and the like, of limb tissue caused by long-time ischemia is avoided.

The invention relates to the technical field of gynecological medical instruments, and discloses an intelligent vagina support system, which comprises a shape memory alloy support skeleton, which comprises a memory alloy skeleton and a connecting ring, the phase change temperature of the shape memory alloy support skeleton is set to be in a human body vagina temperature range, and the shape memory alloy support skeleton is subjected to phase change under temperature triggering and dynamically adapts to pelvic floor muscle stress change; the detachable double-channel medicine bin comprises a detachable antibiotic medicine bin and a detachable estrogen medicine bin which are respectively and correspondingly used for treating infection and vaginal atrophy; and the sensing module comprises an outer insulating layer, an inner electrode and a main body, integrates a pressure sensor and a pH detection electrode, and is used for monitoring environmental parameters in the vagina in real time. The system adopts shape memory alloy as a supporting framework, austenite phase change occurs under triggering of body temperature, and the system is dynamically attached to the anatomical structure of the vagina. Stable radial supporting force is provided during resting and is lower than a mucous membrane ischemia threshold value; when the abdominal pressure suddenly rises during cough or movement, dynamic supporting force compensation is provided through hyperelastic deformation, and instrument displacement or compression injury is effectively prevented.

This disclosure relates to RNAi agents capable of inhibiting complement factor B (CFB) gene expression. Pharmaceutical compositions containing CFB RNAi agents and methods of use thereof are also disclosed. The CFB RNAi agents disclosed herein may be conjugated to a targeted ligand containing an N-acetyl-galactosamine ligand to facilitate in vivo delivery to hepatocytes. RNAi agents can be used in methods of treating diseases, disorders, or conditions partially mediated by CFB gene expression, including IgA nephropathy (IgAN), C3 glomerulopathy (C3G), immune complex-mediated membrane proliferative glomerulonephritis (IC-MPGN), lupus nephritis (LN), anti-glomerular basement membrane antibody disease (anti-GBM), ischemia-reperfusion injury and T-cell-mediated rejection in kidney transplantation (TCMR), anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, age-related macular degeneration (AMD) including early and / or intermediate-stage AMD, geographic atrophy (GA), glaucoma, Doyne honeycomb retinal dystrophy, paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), pre-eclampsia, rheumatoid arthritis (RA), and / or other complement-mediated disorders.

The invention belongs to the technical field of biological medicine and molecular biology, and particularly relates to application of a transcription factor ZHX2 in diagnosis and treatment of hepatic ischemia-reperfusion injury. Specifically, research finds that the expression of ZHX2 after ischemia reperfusion injury is reduced, and HIRI cell necrosis and generation and development of HIRI are obviously promoted by specifically knocking out Zhx2 from liver cells, which are further proved in marginal liver IRI, while the ZHX2 has a protective effect on marginal fatty liver ischemia reperfusion injury. In conclusion, the ZHX2 can be used as a biological marker and a related treatment target of the hepatic ischemia reperfusion injury, especially marginal hepatic ischemia reperfusion injury, so that the ZHX2 has good clinical application value and social benefit.

Liposomal trans-crocetin pharmaceutical compositions, dosing regimens and methods of treating or preventing disorders and conditions associated with, but not limited to, infection, ischemia, hypoxia, ARDS, inflammation, sepsis, shock, stroke, traumatic injury, and proliferative disorders such as cancer are provided. Methods of using the provided trans-crocetin pharmaceutical compositions and dosing regimens to treat cardiovascular, renal, liver, inflammatory, metabolic, pulmonary, neurological, and other disorders and conditions are also provided, as are methods of increasing the delivery of oxygen and increasing the efficacy of a therapeutic agent using the provided compositions and dosing regimens.

The invention relates to the technical field of medicines, in particular to application of mulberry bark extract in preparation of medicines for preventing and / or treating ischemia-reperfusion injury, and finds that morusin administration treatment can effectively relieve pathological injury of mouse liver tissue, reduce activity of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in serum after hepatic ischemia-reperfusion, and can be used for preparing medicines for preventing and / or treating ischemia-reperfusion injury. The expression of inflammatory cytokines is inhibited, and the proportion of apoptotic cells is remarkably reduced. The invention further finds that the morusin inhibits the expression of 15-hydroxyeicosapentaenoic acid (15-HETE), and the protection effect of the morusin on the HIRI can be reversed by adding the 15-HETE, so that the morusin can be used for inhibiting the expression of the 15-hydroxyeicosapentaenoic acid (15-HETE).

The invention concerns the use of compounds represented by formula (I)as inotropic agents. The compounds of formula (I), which include, as preferred, 1-[(1S)-1-(2,3-dichloro-4-methoxyphenyl)ethyl]-3-methyl-3-[(4R)-1-methyl-3,3-dimethyl-4-piperidyl]-urea and its hydrochloride salt, are herein reported to have a significant inotropic activity on cardiomyocytes from both normal and myocardial infarction-induced heart failure animal models, which makes them useful for treating cardiovascular patients in need thereof. Differently from known inotropic agents, the present compounds are effective on cardiomyocyte contractility without influencing calcium mobilization. Accordingly, they are advantageously free from adverse effects caused by increased calcium concentrations, such as increased oxygen demand, tachycardia, arrhythmia, ischemia, etc. Overall, a new, safe and effective inotropic treatment is thus made available.